Additionally, a pan-cancer analysis using TIMER2.0 online tool showed that FXYD2 mRNA expression was also downregulated in bladder cancer, breast cancer, kidney renal papillary cell carcinoma, liver cancer, lung squamous cell carcinoma, prostate cancer, and thyroid cancer, while it was upregulated in cholangiocarcinoma (P < 0.05, Figure S1(h)). Here, FXYD2 is linked to prostate carcinoma.